Larochelle P, Hayness B, Maron N, Dugas S

A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT study

Clin Ther 1994;16:838-53

Hypertension

To evaluate the efficacy and safety of the ACE inhibitor quinapril in hypertension

Open

6 months

3742 patients, median age 56 years, median duration of hypertension 5 years

Quinapril, 10 mg/day initially, titration to BP response, mostly at 2-week intervals, for a maintenance dose of 10-20 mg daily, not to exceed 40 mg/day

Of 2979 patients receiving quinapril at 3 months, 77% were stabilised. Of 2517 patients receiving quinapril at 6 months, 84% were stabilised. There were larger decreases in DBP and SBP in patients who continued quinapril than in those who stopped it. Response to quinapril was similar in newly diagnosed patients and those with a history of hypertension. 980 patients (26.2%) reported adverse events, most frequently cough, which was considered definitely connected with quinapril in 3.6% of cases. Serious adverse events occurred in 55 patients (1.5%) and were considered possibly connected with quinapril in three cases. Adverse events were reported significantly more frequently by patients who received the detailed consent form than by those who received the abbreviated one (p = 0.004)